C60 Advances 2024https://www.youtube.com/watch?v=Duo2U5Wi5w0
There are many papers in google scholar: https://scholar.google.ca/scholar?q=2024+research+in+carbon+60+fullerenes+for+health+related+issues&hl=en&as_sdt=0&as_vis=1&oi=scholart
Big Pharma can not ignore Voy, the only company with low cost C60, that is made from captured CO2, and the first sustainable drug devellopment program in the world. Big Pharma is all about sustainability and UN agenda 2030. The carbon capture puts Voy on a entirely new level which is being 100% ignored and they are way undervalued from this aspect.
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are being integrated into the drug procurement process in different nations. https://pharmaboardroom.com/articles/sustainability-pharma-procurement-in-europe-are-you-green-enough/